Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment
08 Agosto 2023 - 5:05PM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, and Intermountain Precision Genomics, part
of the Intermountain Health system, will begin providing oncology
test results that allow access to the ComboMATCH trials. ComboMATCH
is a coordinated platform of clinical oncology trials sponsored by
the National Cancer Institute (NCI), part of the National
Institutes of Health. Led by the NCI and the ECOG-ACRIN Cancer
Research Group (ECOG-ACRIN), ComboMATCH aims to help identify and
show the efficacy of new anti-cancer drug combinations for patients
with locally advanced or metastatic solid tumor cancers.
ComboMATCH includes a Patient Registration Trial
led by ECOG-ACRIN, along with several treatment trials designed and
led by the Alliance for Clinical Trials in Oncology, Children’s
Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and
SWOG Cancer Research Network. These groups are members of the NCI’s
National Clinical Trials Network (NCTN).
In ComboMATCH, researchers in the NCTN groups will
seek to improve cancer patient outcomes using new combinations of
biomarker targeted therapies beyond the current standard of care.
To be selected for the trial, combinations must show evidence they
may be more effective than single therapy in treating cancer.
Patients with locally advanced or metastatic cancer with eligible
genetic testing completed through Intermountain or Myriad may have
the opportunity to enroll in the ComboMATCH Patient Registration
Trial (EAY191) to receive these types of combination therapies to
target genetic mutations in their tumor cells and/or their
germline.
“The ComboMATCH clinical trials are critically
important for the advancement of precision oncology care,
showcasing how genetic insights can help determine more targeted
treatment decisions for patients with cancer,” said Michael Lyons,
general manager of oncology, Myriad Genetics. “Our strong
partnership with Intermountain enables us to continually
collaborate and innovate together to provide comprehensive genomic
profiling options that can help guide clinical care and improve
outcomes for patients.”
In 2021, Myriad and Intermountain announced a
collaboration on a comprehensive offering of germline and somatic
tumor testing, known as Precise™ Oncology Solutions, leveraging the
strengths of Myriad’s MyRisk® germline test and Intermountain’s
somatic Theramap assay. Both the Myriad and Intermountain tests are
now able to be used to identify patients that may be eligible for
enrollment in a treatment study under ComboMATCH.
“Clinical trials like ComboMATCH present a unique
opportunity for patients to get treatments, in this case, powerful
targeted treatment combinations, that would otherwise not be
available,” said Jason Gillman, Intermountain Precision Genomics
Health Operations director. “This is especially valuable to the
advanced cancer patients that TheraMap was designed to help.”
Visit myriad.com/hcp-precise-oncology-solutions/ or
IntermountainHealthcare.org/TheraMap for more information on
germline and somatic testing.
To learn more about ComboMATCH, visit
https://ecog-acrin.org/combomatch.
For general information about ComboMATCH, visit
https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/combomatch.
About Myriad GeneticsMyriad
Genetics is a leading genetic testing and precision medicine
company dedicated to advancing health and well-being for all.
Myriad develops and offers genetic tests that help assess the risk
of developing disease or disease progression and guide treatment
decisions across medical specialties where genetic insights can
significantly improve patient care and lower healthcare costs. For
more information, visit www.myriad.com.
About Intermountain
HealthHeadquartered in Utah with locations in seven states
and additional operations across the western U.S., Intermountain
Healthcare is a nonprofit system of 33 hospitals, 385 clinics,
medical groups with some 3,900 employed physicians and advanced
care providers, a health plans division called
SelectHealth with more than one million members, and other
health services. Helping people live the healthiest lives possible,
Intermountain is committed to improving community health and is
widely recognized as a leader in transforming healthcare by using
evidence-based best practices to consistently deliver high-quality
outcomes at sustainable costs.
Intermountain Healthcare media contact: Brad
Gillman: brad.gillman@imail.org / (385) 315-8949
Safe Harbor StatementThis press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
that patients with locally advanced or metastatic cancer with
eligible genetic testing completed through Intermountain or Myriad
may have the opportunity to enroll in the ComboMATCH Patient
Registration Trial. These “forward-looking statements” are
management’s expectations of future events as of the date hereof
and are subject to known and unknown risks and uncertainties that
could cause actual results, conditions, and events to differ
materially and adversely from those anticipated. Such factors
include those risks described in the company’s filings with the
U.S. Securities and Exchange Commission, including the company’s
Annual Report on Form 10-K filed on March 1, 2023, as well as any
updates to those risk factors filed from time to time in the
company’s Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. Myriad is not under any obligation, and it expressly disclaims
any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise
except as required by law.
Media Contact:Glenn Farrell (385)
318-3718PR@myriad.com
Investor Contact: Matt Scalo(801)
584-3532IR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024